Equine standing sedation: detomidine vs romifidine vs xylazine — POSSIBLE

In horses, do detomidine, romifidine, and xylazine differ in depth/duration of sedation and ataxia for standing procedures?

Shelf #322 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE: Small crossover experiments agree on the pattern rather than on any one drug 'winning'. At doses considered equipotent, all three alpha-2 agonists sedate; romifidine's effects last longest (nociceptive-withdrawal thresholds stayed raised for 120 minutes after romifidine vs 100 minutes after detomidine and 60 minutes after xylazine in a blinded randomised crossover, and accelerometry likewise found more prolonged effects with romifidine), while detomidine and xylazine produced greater head lowering and more ataxia than romifidine at equipotent doses in the earliest head-to-head study. In the one blinded clinical study (30 horses sedated for dental rasping), detomidine 20 μg/kg matched romifidine 120 μg/kg for depth but romifidine 80 μg/kg for duration, with no difference in procedure scores. Every carded study is tiny (5–30 horses) and mostly experimental rather than clinical, which caps this shelf at POSSIBLE. Drafted Nov 10, 2026 (VetMed build, topic #322); all figures from abstracts fetched and verified at drafting.

England 1992: romifidine 80 μg/kg equipotent to xylazine 1 mg/kg and detomidine 20 μg/kg, but detomidine and xylazine caused more head lowering and ataxia

Comparative study, Latin-square design (record's own publication types; randomisation not stated)

Who: Horses: 5 horses in an experimental setting, each treated intravenously with two doses of romifidine (40 and 80 micrograms/kg body weight), two doses of detomidine (10 and 20 micrograms/kg body weight) and one dose of xylazine (1 mg/kg body weight) using a Latin-square design.

Result: The dose of 80 micrograms/kg romifidine appeared equipotent to 1 mg/kg xylazine and 20 micrograms/kg detomidine, although at these doses both xylazine and detomidine had a shorter action. Detomidine 20 micrograms/kg and xylazine both produced greater lowering of the head and a greater degree of ataxia than romifidine at either dose. Romifidine produced sedation similar to that of the other drug regimes, and the effect upon imposed stimuli was similar.

Watch out: Only 5 horses, and the record does not state that treatment order was randomised or that assessors were blinded — neither is claimed here. 'Equipotent' is the authors' judgement from this small experiment, and dose comparisons drive every conclusion on this shelf: a different dose ratio could reorder the drugs.

England GC, Clarke KW, Goossens L. A comparison of the sedative effects of three alpha 2-adrenoceptor agonists (romifidine, detomidine and xylazine) in the horse. J Vet Pharmacol Ther. 1992;15(2):194-201. PMID: 1359161. Registry ID: none in the record. MeSH: Acoustic Stimulation · Adrenergic alpha-Agonists/pharmacology · Animals · Ataxia/chemically induced,veterinary · Heart Rate/drug effects · Horse Diseases/chemically induced · Horses/physiology · Hypnotics and Sedatives/pharmacology · Imidazoles/pharmacology · Male · Penis/drug effects · Photic Stimulation · Physical Stimulation · Sweating/drug effects · Urination/drug effects · Xylazine/pharmacology

Freeman & England 2000: detomidine 20 μg/kg equalled romifidine 120 μg/kg for depth of sedation but romifidine 80 μg/kg for duration in horses sedated for dentistry

Blinded comparative clinical study (record's own wording; randomisation not stated)

Who: Horses: 30 horses requiring sedation for routine dental treatment in a clinical setting, given intravenous romifidine (80 or 120 microg/kg) or detomidine (20 microg/kg); teeth were rasped 30 minutes after administration and parameters were followed for two hours.

Result: Romifidine produced a dose-dependent effect on most parameters. Detomidine at 20 microg/kg was similar to romifidine at 120 microg/kg in the magnitude of its sedative effects, but was similar to romifidine at 80 microg/kg in its duration. There were no significant differences between the three treatments in terms of the clinical procedure score.

Watch out: The draft anchor for this shelf named this study as a three-drug comparison — it is not: there is no xylazine arm. The record establishes a blinded study in its abstract but does not state random allocation, and the publication types index it only as a Comparative Study, so randomisation is not claimed. Procedure scores — the outcome closest to practice — did not differ between treatments.

Freeman SL, England GC. Investigation of romifidine and detomidine for the clinical sedation of horses. Vet Rec. 2000;147(18):507-11. PMID: 11110491. Registry ID: none in the record. MeSH: Analgesics · Analysis of Variance · Anesthetics · Animals · Procedural Sedation/veterinary · Female · Horses · Imidazoles

Hamm 1995: in a double-blind study, detomidine sedation was deeper and longer than romifidine at recommended doses, with more instability and ataxia

Double-blind randomised study with placebo (record's own wording and publication types)

Who: Horses: 8 horses in an experimental setting, treated intravenously at seven-day intervals with detomidine at doses of 10, 20 and 40 micrograms/kg, romifidine at doses of 40, 80 and 120 micrograms/kg, or a placebo solution, with objective measurements and clinician evaluation at 15-minute intervals for three hours.

Result: The administration of both drugs at all doses resulted in sedation. The sedation achieved with romifidine was significantly shallower and shorter-lived than with detomidine at the recommended doses (P < 0.05). Detomidine at the 10 micrograms/kg dose was similar in its effects to the two highest doses of romifidine. Instability and ataxia were more pronounced with detomidine than with romifidine but the effects were only slight to moderate and not regarded as a hindrance to procedures for which sedation is needed. Bradycardia was evident with both drugs at all doses.

Watch out: Detomidine-versus-romifidine only — no xylazine arm — and 8 horses. This card sits in some tension with Rohrbach 2009 below (romifidine longest-acting): the studies used different dose pairings and different endpoints (clinical sedation scores vs reflex thresholds), which is exactly why this shelf is POSSIBLE rather than higher. Analgesia findings from this record (detomidine dose-dependent, romifidine none detected) are outside this shelf's sedation question.

Hamm D, Turchi P, Jöchle W. Sedative and analgesic effects of detomidine and romifidine in horses. Vet Rec. 1995;136(13):324-7. PMID: 7604508. Registry ID: none in the record. MeSH: Analgesics/administration & dosage,adverse effects,pharmacology · Anesthetics/administration & dosage,adverse effects,pharmacology · Animals · Ataxia/chemically induced,veterinary · Bradycardia/chemically induced,veterinary · Dose-Response Relationship, Drug · Double-Blind Method · Electric Stimulation · Female · Heart Rate/drug effects · Horse Diseases/chemically induced · Horses/physiology · Imidazoles/administration & dosage,adverse effects,pharmacology · Injections, Intravenous/veterinary · Male · Motor Activity/drug effects · Pain/drug therapy,etiology,veterinary

Rohrbach 2009: at equipotent sedative doses, antinociceptive duration was longest with romifidine (120 min), then detomidine (100 min), then xylazine (60 min)

Prospective, blinded, randomized cross-over study (record's own wording)

Who: Horses: 10 healthy adult horses weighing 527-645 kg and aged 11-21 years old, standing in an experimental setting; each received a single intravenous bolus of detomidine 0.02 mg/kg, romifidine 0.08 mg/kg, or xylazine 1 mg/kg, with nociceptive withdrawal reflex and temporal summation thresholds measured repeatedly to 130 minutes and depth of sedation assessed at each time point.

Result: The administration of detomidine, romifidine and xylazine significantly increased the current intensities necessary to evoke the nociceptive withdrawal reflex and temporal summation in thoracic and pelvic limbs compared with baseline. Xylazine increased withdrawal-reflex thresholds over baseline for 60 minutes, while detomidine and romifidine increased them for 100 and 120 minutes, respectively. Temporal summation thresholds were significantly increased for 40, 70 and 130 minutes after xylazine, detomidine and romifidine, respectively. The extent of maximal increase of both thresholds was comparable between drugs, while the duration of action was drug-specific.

Watch out: The duration figures are for reflex thresholds (an antinociception endpoint), not for clinical sedation depth — sedation depth was assessed but the abstract reports no between-drug sedation-depth result, so this card carries the duration claim only in that qualified sense. Ten horses, experimental setting, single bolus doses chosen as equipotent for sedation by the authors.

Rohrbach H, Korpivaara T, Schatzmann U, Spadavecchia C. Comparison of the effects of the alpha-2 agonists detomidine, romifidine and xylazine on nociceptive withdrawal reflex and temporal summation in horses. Vet Anaesth Analg. 2009;36(4):384-95. PMID: 19538573. Registry ID: none in the record. MeSH: Animals · Cross-Over Studies · Female · Forelimb · Hindlimb · Horses · Imidazoles/pharmacology · Male · Pain/drug therapy,veterinary · Reflex · Time Factors · Xylazine/pharmacology

López-Sanromán 2013: accelerometry showed more prolonged sedative effects with romifidine than with xylazine or detomidine

Randomized controlled trial, cross-over with saline control (record's publication types and abstract wording)

Who: Horses: 6 healthy horses in an experimental setting; each horse was injected intravenously, in random order, with saline (0.9% NaCl) solution (10 mL), xylazine diluted in saline (0.5 mg/kg), detomidine diluted in saline (0.01 mg/kg), or romifidine diluted in saline (0.04 mg/kg), with triaxial accelerometric gait assessment before and up to 120 minutes after each treatment.

Result: Significant differences were evident in stride frequency and regularity between treatments with saline solution and each alpha2-adrenoceptor agonist drug; in speed, dorsoventral power, propulsive power, total power, and force values between treatments with saline solution and detomidine or romifidine; and in mediolateral power between treatments with saline solution and detomidine. Stride length did not differ among treatments. Accelerometric evaluation revealed more prolonged sedative effects of romifidine, compared with effects of xylazine or detomidine.

Watch out: Six horses, and the doses are lower than the equipotent doses used in England 1992 and Rohrbach 2009 (notably xylazine 0.5 mg/kg and romifidine 0.04 mg/kg), so this study compares these doses, not the drugs at every dose. Accelerometric gait variables are an objective proxy for sedation/ataxia, not a clinical procedure outcome; blinding of assessors is not stated in the record and is not claimed.

López-Sanromán FJ, Holmbak-Petersen R, Varela M, del Alamo AM, Santiago I. Accelerometric comparison of the locomotor pattern of horses sedated with xylazine hydrochloride, detomidine hydrochloride, or romifidine hydrochloride. Am J Vet Res. 2013;74(6):828-34. PMID: 23718649. Registry ID: none in the record. MeSH: Accelerometry/veterinary · Anesthetics/pharmacology · Animals · Biomechanical Phenomena · Cross-Over Studies · Female · Gait/drug effects · Horses/physiology · Hypnotics and Sedatives/pharmacology · Imidazoles/pharmacology · Male · Motor Activity/drug effects · Xylazine/pharmacology

Synthesis: yes, they differ — romifidine lasts longest and is kindest to balance; detomidine is deeper at label-type doses; all findings rest on very small studies

Synthesis

Who: Synthesis of the cards above: England 1992 (5 horses, Latin-square), Hamm 1995 (8 horses, double-blind, placebo-controlled), Freeman & England 2000 (30 horses, blinded, dental procedures), Rohrbach 2009 (10 healthy adult horses, blinded randomised cross-over) and López-Sanromán 2013 (6 healthy horses, randomised cross-over with saline).

Result: Across designs, the consistent findings are: (1) duration — romifidine outlasts detomidine, which outlasts xylazine, at doses the investigators judged equipotent (reflex thresholds 120 vs 100 vs 60 minutes; accelerometry concordant); (2) ataxia/balance — detomidine and xylazine lowered the head more and produced more ataxia than romifidine at equipotent doses, and detomidine caused more instability than romifidine in the double-blind study, though only slight to moderate; (3) depth — detomidine at 20 μg/kg matched a high romifidine dose (120 μg/kg) for magnitude of sedation in the clinical dental study, and clinical procedure scores did not differ. No study was large, and dose choice can move the ranking, so these are working distinctions for standing procedures, not verdicts.

Watch out: Four of five carded studies are experimental (healthy horses, stimuli or gait tests), not horses undergoing real procedures; the one clinical study had no xylazine arm and found no difference in procedure score. Combinations with opioids or other agents — common in practice — are outside these records.

Synthesis of England GC et al. PMID: 1359161; Freeman SL, England GC. PMID: 11110491; Hamm D et al. PMID: 7604508; Rohrbach H et al. PMID: 19538573; López-Sanromán FJ et al. PMID: 23718649. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.